Traders should monitor for potential coverage expansions by payers and future data readouts from the larger ProtecT trial, which could serve as a catalyst for broader commercial adoption and valuation re-rating.
Price Chart
Executive Summary
Mdxhealth highlighted new data from the Oxford-led ProMPT study showing its GPS mdx genomic test can predict favorable outcomes in prostate cancer patients across multiple treatment settings, supporting its use in guiding treatment de-escalation and avoiding overtreatment. The results were presented at the EAU 2026 conference and represent a key milestone in the ongoing GPS-ProtecT study collaboration with Oxford.
Key Facts
- New data from the GPS-ProMPT study (n=409) show GPS mdx test effectively stratifies risk of treatment failure in localized prostate cancer across active surveillance, surgery, and radiotherapy.
- Six-year freedom-from-failure was 92% in active surveillance patients and up to 100% in surgery/radiotherapy patients with favorable GPS scores, even among clinically high-risk groups.
- Results presented at EAU 2026 by Professor Freddie Hamdy, University of Oxford, a leading prostate cancer researcher.
- Part of broader GPS-ProtecT study collaboration with Oxford, leveraging long-term data from the landmark UK ProtecT trial (n>1,500).
- GPS mdx is a 17-gene assay that assesses tumor biology to guide personalized treatment decisions between active surveillance and definitive therapy.
Financial Impact
Potential for increased adoption and reimbursement as clinical validation strengthens; no direct financial figures reported.
Risk Factors
- No immediate revenue impact; clinical adoption and reimbursement may lag despite strong data.
- Forward-looking statements about future benefits are subject to regulatory, payer, and market acceptance risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256649 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | 6-K | $0.2070 $0.1830 | ▲ +11.59% | ▲ +11.69% | $0.1899 (+8.26%) |
Oct 15, 2026 11d ago | SC 13D/A | $0.2066 $0.1833 | ▲ +11.28% | ▲ +10.85% | $0.1899 (+8.08%) |
Oct 15, 2026 11d ago | Press Release | $0.2066 $0.1833 | ▲ +11.28% | ▲ +10.85% | $0.1899 (+8.08%) |
Sep 17, 2026 5w ago | 144 | $0.6300 $0.5650 | ▲ +10.32% | ▲ +11.59% | $0.1899 (+69.86%) |
Sep 3, 2026 7w ago | 6-K | $0.7484 $0.7072 | ▲ +5.51% | ▲ +4.30% | $0.1899 (+74.63%) |
Aug 13, 2026 10w ago | 6-K | $0.8080 $0.7431 | ▲ +8.03% | ▲ +6.66% | $0.1899 (+76.50%) |
Aug 13, 2026 10w ago | Press Release | $0.8080 $0.7431 | ▼ −8.03% | ▼ −6.66% | $0.1899 (−76.50%) |
Jul 24, 2026 13w ago | 6-K | $0.4180 $0.4180 | · 0.00% | ▲ +1.07% | $0.1899 (+54.57%) |
Jul 2, 2026 16w ago | Press Release | $0.4765 $0.4899 | ▼ −2.81% | ▼ −1.88% | $0.1899 (+60.15%) |
Apr 29, 2026 25w ago | 6-K | $2.04 $2.01 | ▼ −1.47% | ▼ −3.20% | $0.1899 (−90.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers